Autopsy report · NCT01053975

SPIROCOR Coronary Outcome by Respiratory Stress Examination

“Based on analyses of studies separately of the SCORE study, sponsor has decided to discontinue the Study. Data collected during the study will not be analyzed”

The sponsor’s own words in the registry.

Life of this trial

• 1,000 participants planned (an estimate, not an actual count).
• No results are posted on the registry.

Vital statistics

Status

Terminated

Sponsor

Spirocor

Sponsor type

Industry

Conditions

Severe Coronary Artery Disease (S-CAD)

Participants

1,000 (planned, not actual)

Sites

29

Countries

United States

Trials that died the same way

• Consolidation Therapy in Patients With Metastatic Solid Malignancies
  “Sponsor decision to discontinue study.” (78% match in meaning)
• A Study of Pemetrexed Maintenance With or Without ADXS11-001 Immunotherapy in Patients With Human Papillomavirus Positive (HPV+), NSCLC Following First-Line Induction Chemotherapy
  “Study was withdrawn per sponsor decision” (75% match in meaning)
• Trial of Erlotinib in Patients With JAK-2 V617F Positive Polycythemia Vera
  “The study was terminated by the sponsor” (74% match in meaning)
• Safety Study of Intranasal Etripamil for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia (PSVT). NODE-302
  “Study was stopped by the Sponsor” (74% match in meaning)
• Study to Evaluate the Efficacy and Safety of Armodafinil as Treatment for Patients With Excessive Sleepiness Associated With Mild or Moderate Closed Traumatic Brain Injury
  “Study has been stopped by sponsor decision.” (74% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.